Dengue structural proteins as antiviral drug targets: Current status in the drug discovery & development

Akshatha H S,Gurubasavaraj V Pujar,Arun Kumar Sethu,Meduri Bhagyalalitha,Manisha Singh
DOI: https://doi.org/10.1016/j.ejmech.2021.113527
2021-10-05
Abstract:Dengue virus belongs to the class of RNA viruses and subclass of enveloped single-stranded positive-sense RNA virus. It causes dengue fever (DF), dengue hemorrhagic fever (DHF), or dengue shock syndrome (DSS), where DHF and DSS are life-threatening. Even though dengue is an age-old disease, it is still a mystery and continues to be a global threat. Numerous attempts have been carried out in the past few decades to eradicate the virus through vaccine and antiviral drugs, but still battle continues. In this review, the possible drug targets for discovery and development of potential antiviral drugs against structural proteins of dengue virus, the current development status of the antiviral drugs against dengue around the world, and challenges that need to be addressed to overcome the shortcomings in the process of drug discovery have been discussed.
What problem does this paper attempt to address?